zantriocom
Newbie
- Messages
- 7
- Likes
- 0
(COO) - buy
Cooper, fiscal 1Q profit surges. Company earned $23.9 mln, or 53 cents per share, for the quarter ended Jan. 31, compared with net income of $6.9 mln, or 15 cents per share, during the same period a year prior.
(ARST) - buy
ArcSight, Q3 profit beats Street, sees strong Q4. Co issues upside guidance for FY09, sees EPS of $0.41-0.48 vs. $0.29 consensus; sees FY09 revs of $130.9-134.9 vs. $127.34 mln consensus.
(IPI) - short
Intrepid Potash, earnings preview. IPI has a short history as the IPO was issued in April of 2008. Since then, the co missed by $0.07 in the most recent quarter (Q3). The current quarter provides more uncertainty following the reduction in sales by 50%.
(EBS) - short
Emergent BioSolutions, 4Q profit plunges. Company set its revenue outlook well below Wall Street forecasts.
(SEPR) - short
Sepracor, reports preliminary Phase II study results for SEP-225441 for the treatment of generalized anxiety disorder, did not meet its primary efficacy endpoint.
Cooper, fiscal 1Q profit surges. Company earned $23.9 mln, or 53 cents per share, for the quarter ended Jan. 31, compared with net income of $6.9 mln, or 15 cents per share, during the same period a year prior.
(ARST) - buy
ArcSight, Q3 profit beats Street, sees strong Q4. Co issues upside guidance for FY09, sees EPS of $0.41-0.48 vs. $0.29 consensus; sees FY09 revs of $130.9-134.9 vs. $127.34 mln consensus.
(IPI) - short
Intrepid Potash, earnings preview. IPI has a short history as the IPO was issued in April of 2008. Since then, the co missed by $0.07 in the most recent quarter (Q3). The current quarter provides more uncertainty following the reduction in sales by 50%.
(EBS) - short
Emergent BioSolutions, 4Q profit plunges. Company set its revenue outlook well below Wall Street forecasts.
(SEPR) - short
Sepracor, reports preliminary Phase II study results for SEP-225441 for the treatment of generalized anxiety disorder, did not meet its primary efficacy endpoint.